Canopy Growth — Q2 FY2027 Earnings Summary

Canopy Growth Corporation reported a 22% increase in consolidated net revenue to $81.4 million for the second quarter of fiscal year 2027, driven primarily by a 141% surge in international cannabis sales. The company's cannabis segment revenue grew 30% year-over-year, with specific gains of 18% in Canadian medical cannabis and 17% in Canadian adult-use cannabis. Adjusted EBITDA loss narrowed to $2.9 million, reflecting continued progress toward profitability despite a reported net loss of $40.7 million due to fair value charges on Canopy USA assets. Strategic milestones included the EU GMP certification of the Smiths Falls facility and the expansion of medical cannabis distribution into the United Kingdom and Australia.